News
12-24-2009, 04:24 AM
The aromatase inhibitor letrozole (Femara) produces a significant survival benefit over tamoxifen when used as adjuvant therapy for postmenopausal women with endocrine-responsive breast cancer, according to updated results of a major trial released in a plenary session at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS)...
More... (http://www.medicalnewstoday.com/articles/174758.php)
More... (http://www.medicalnewstoday.com/articles/174758.php)